Related references
Note: Only part of the references are listed.Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR
E. Kinz et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients
Valerie Taly et al.
CLINICAL CHEMISTRY (2013)
JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse
Thoralf Lange et al.
HAEMATOLOGICA (2013)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory
Jason D. Merker et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype
Thomas Stauffer Larsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a
Jean-Jacques Kiladjian et al.
BLOOD (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Share Paper
